Announcement • Dec 23
Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million. Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 776,567,389
Price\Range: AUD 0.003
Discount Per Security: AUD 0.00018
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 690,099,278
Price\Range: AUD 0.003
Discount Per Security: AUD 0.00018
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Oct 27
Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025 Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 3, 62 lygon street, carlton, victoria 3053, Australia Announcement • Oct 10
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 164,307,917
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,092,679,329
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 387,577,500
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,435,254
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Transaction Features: Subsequent Direct Listing Announcement • May 20
Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million. Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 164,300,000
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,485,700,000
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Apr 24
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 197,203,052
Price\Range: AUD 0.005
Discount Per Security: AUD 0.0001
Transaction Features: Rights Offering Announcement • Mar 04
Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million. Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 638,059,938
Price\Range: AUD 0.005
Discount Per Security: AUD 0.0003
Transaction Features: Rights Offering Announcement • Feb 13
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: AUD 0.005
Transaction Features: Subsequent Direct Listing Announcement • Dec 09
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 69,990,973
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 430,009,027
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 125,000,000
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing Announcement • Oct 23
Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 69,990,973
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 430,009,027
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 125,000,000
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing Announcement • Oct 14
Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024 Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024. Location: at level 3, 62 lygon street, carlton, victoria 3053 Australia Announcement • Jan 18
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 273,717,042
Price\Range: AUD 0.028
Transaction Features: Rights Offering Announcement • Nov 01
Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101 Chimeric Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers. The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. CHM 2101 is a 3rd generation, novel CDH 17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, gastric Cancer and Neuroendocrine Tumours. These experiments demonstrated that CHM 2101 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues. With the FDA IND clearance Chimeric will now begin the initiation of a phase 1/2 multi-site clinical trial in patients with advanced ColorectAL Cancer, Gastric Cancer and neuroendocrine Tumours. The study is planned to begin patient enrollment in 2024. Announcement • Oct 16
Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023 Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023, at 11:01 AUS Eastern Standard Time. Location: Level 3, 62 Lygon Street, Carlton Victoria Australia Agenda: To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2023; to consider the Remuneration Report; to consider Election of Director Mr Phillip Hains; to consider Election of Director Mr Eric Sullivan; to consider and Approval of 10% capacity under Listing Rule 7.1A; to consider the Renewal of Omnibus Incentive Plan; to consider Approval to issue Incentive Options to Director Mr Eric Sullivan; to consider Ratification of agreement to issue Shares to Lind Global Fund II LP; to consider Amendment to Constitution; and to consider other matters. Announcement • Aug 30
Chimeric Therapeutics Limited Announces Board Changes Chimeric Therapeutics announced the appointment of Mr. Eric Sullivan as a Non-Executive Director, effective 30 August 2023. Mr. Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Mr. Sullivan replaces the outgoing Ms Cindy Elkins, who is stepping down from the Chimeric Board of Directors. Announcement • Aug 03
Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director Chimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company. Announcement • Jul 12
Chimeric Therapeutics Limited Announces Board Changes Chimeric Therapeutics announces that Ms Leslie Chong has resigned from her position as Non-Executive Director to focus on her duties as Chief Executive Officer of Imugene Limited.Leslie has served on the Chimeric Board since August 2020 and has provided valued contributions and experienced counsel to the Company. Following the resignation, the Board has appointed Phillip Hains to fill a casual vacancy. Phillip is the Company's CFO and Joint Company Secretary and Principal of Melbourne based "The CFO Solution". Announcement • Jun 05
Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical Trial Chimeric Therapeutics announced activation of a Phase 1B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM) to assess the safety and efficacy of CHM 1101, the company's first in class CLTX CAR T cell therapy. The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas. This Phase 1B trial, being conducted under a US IND, is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule. Part A of the trial will enroll 3-6 patients at the highest dose tested in the ongoing clinical trial at City of Hope Cancer Centre. In late 2023, Chimeric will assess the clinical safety and activity from the CHM 1101 clinical program. Based on a favorable review of the results of that assessment, Part B of the trial, a dose expansion cohort, will be opened to enroll 12 to 26 additional patients. Upon successful completion of the Part B dose expansion cohort, the Company intends to design and initiate a registration trial, in collaboration with global regulatory feedback. CHM 1101 (CLTX CAR T) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope. CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumor-targeting component of the chimeric antigen receptor (CAR). CHM 1101 CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. In preclinical models, CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile. CHM 1101 is currently being studied in a Phase 1B clinical trial in recurrent /progressive glioblastoma. Initial positive data from the investigator-initiated Phase 1A trial has been presented on patients treated in the first two dose levels of the trial. Announcement • Jan 24
Chimeric Therapeutics Limited Announces Successful Completion of 28-Day Follow Up Period for 3rd Patient Cohort in Brain Cancer Phase 1 Trial Chimeric Therapeutics provided an update to 22 December 2022 announcement and confirm that all patients dosed in the 3rd patient cohort in City of Hope National Medical Center's phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial have now advanced beyond the 28-day follow up period without experiencing dose- limiting toxicities. Patients in the 3rd dose cohort received a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cellsthrough dual routes of intratumoral (ICT) and intraventricular (ICV) administration. Achievement of this milestone enables the trial to advance to the 4th and final dose cohort wherein subjects will be treated with a total dose of 440 X 106 CHM 1101 CAR T cells by ICT and ICV administration. City of Hope, one of the larger cancer research and treatment organizations in the United States, initiated and is leading the current Phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial. Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the chlorotoxin CAR-T cells from City of Hope. The Phase 1A study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across four dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a phase 2 trial. CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent /progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma. CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours. CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers. Announcement • Jan 20
Chimeric Therapeutics Announces First Patient Dosed in CHM 0201 Vactosertib Trial Chimeric Therapeutics, announced that the first patient has been dosed in the CHM 0201 (CORE NK) + Vactosertib clinical trial, the first ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. The CHM 0201 (CORE NK) platform is a potential best in class NK cell platform of ex-vivo expanded non HLA-matched universal donor NK cells. The platform was previously studied in a phase 1 clinical trial that established safety with no GvHD (Graft versus Host Disease), 28-day NK cell persistence and an encouraging early efficacy signal, particularly in blood cancers where all patients achieved disease control and one patient achieved a complete response that was sustained for over 15 months at time of study publication. The objective of this new Phase 1B study is to build upon the clinical responses seen in the initial CORE NK Phase 1A clinical trial by adding Vactosertib, an oral TGF- receptor inhibitor that can potentially disrupt the TGF- signaling pathway. This new trial is being led by UH Seidman oncologist J. Eva Selfridge, MD, PhD, and Assistant Professor at Case Western Reserve University School of Medicine in Ohio and is designed to treat 12 patients with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers. The Phase 1B trial is currently funded without financial support from Chimeric Therapeutics.